Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV ... ( New HIV Viral Load Assay Develope...)

Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring

Date:11/30/2007

New HIV Viral Load Assay Developed Specifically for Resource-Limited

Settings Joins Global Procurement Consortium

UPPSALA, Sweden, November 30 /PRNewswire/ -- Cavidi AB, a producer of medical diagnostic products, today announced an agreement with the Clinton Foundation HIV/AIDS Initiative (CHAI). Under the agreement, Cavidi's ExaVir(TM) Load assay will be immediately available to members of CHAI's Procurement Consortium at a discounted price. With more than 70 developing countries in the consortium, the agreement is a significant step in making viral load monitoring more accessible to HIV-positive patients in the developing world.

Viral load monitoring is essential for the proper management of HIV-positive patients being treated with antiretroviral drugs (ARVs). The test helps doctors use ARVs more effectively to extend a patient's length and quality of life, limit the development of viral resistance and minimize waste of medication. "Viral load testing is an essential part of HIV management. As more people in the developing world gain access to ARVs, it's important that access to viral load testing keeps pace," said Cavidi CEO Martyn Eales. "It's Cavidi's goal to make monitoring more accessible in all countries. I'm very pleased with our partnership with President Clinton's Foundation because it brings us closer to reaching that goal."

Although viral load monitoring has been a standard part of treatment in developed countries, it has been considered impractical for use in developing nations where HIV infection is most widespread. That is because traditional viral load tests are expensive and require technically advanced laboratory facilities. ExaVir Load is the first HIV viral load test designed to overcome these obstacles. Several independent studies have shown the assay to be as accurate and reliable as any other commercially available test, with the added benefit of being able to detect all known subtypes of HIV. Thi
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. New Investors Fund Expansion of Cavidi AB
2. Pot bellies linked to early signs of cardiovascular disease
3. MSU engineering team designs innovative medical device
4. Jump in Youth Suicide Prompts National Childrens Charity KidsPeace to Issue Tips on Prevention, Warning Signs
5. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
6. Gov. Blagojevich Signs Bill Improving Illinois Mental Illness Treatment Law
7. A new technology for cancer screening listens for the signs of cancer
8. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
9. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
10. Former Ronco President Tim Dupler Signs International Direct Sales and Marketing Contract with Natural Nutrition
11. KARL LAGERFELD SAS Signs Global Eyewear License Agreement With Marchon Eyewear, Inc.

Post Your Comments:

Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV ...( New HIV Viral Load Assay Develope...),Health